We would like to be able to move this CAR T-cell treatment to an earlier stage. For example, once we know enough about the efficacy, we can consider moving this to patients. For example, after initial failed induction treatment, after the first or second line of treatment, we can also consider maybe use this CAR T-cell therapy in a maintenance or consolidation strategy in patients with minimal residual disease. So patient will benefit much earlier on rather than waiting for them to have multiple prior lines of therapies and really not in a good medical condition to really go through CAR T-cell therapies, so making it available for more patients.